News und Analysen
EQS-News: M1 Kliniken AG publishes preliminary figures for the 2024 financial year: Strong EBIT growth (+70%) and significant increase in earnings per share (+57%)
EQS-News: M1 Kliniken AG publishes preliminary figures for the 2024 financial year: Strong EBIT growth (+70%) and significant increase in earnings per share (+57%)
EQS-News: Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm
EQS-News: Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm
EQS-News: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
EQS-News: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
EQS-News: Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024
EQS-News: Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024
EQS-Adhoc: FamiCord AG significantly exceeds annual earnings guidance for 2024 on the basis of preliminary figures
EQS-Adhoc: FamiCord AG significantly exceeds annual earnings guidance for 2024 on the basis of preliminary figures
EQS-News: Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig
EQS-News: Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig
EQS-Adhoc: M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment
EQS-Adhoc: M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment
EQS-News: MEDICLIN ends successful 2024 financial year
EQS-News: MEDICLIN ends successful 2024 financial year
EQS-News: Eckert & Ziegler: Record year 2024 with new all-time highs
EQS-News: Eckert & Ziegler: Record year 2024 with new all-time highs
EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
EQS-News: Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities
EQS-News: Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities
EQS-News: Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
EQS-News: Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
EQS-News: Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply
EQS-News: Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply
EQS-News: MEDICLIN invites you to the 2025 virtual press conference on the financial statements for the year 2024
EQS-News: MEDICLIN invites you to the 2025 virtual press conference on the financial statements for the year 2024
EQS-News: Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG
EQS-News: Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG
EQS-News: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
EQS-News: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
EQS-Adhoc: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
EQS-Adhoc: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
EQS-News: FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
EQS-News: FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
EQS-News: Eckert & Ziegler Enters Strategic Partnership with Bicycle Therapeutics for Radioisotope Supply and Contract Development and Manufacturing of Bicycle Radio Conjugates
EQS-News: Eckert & Ziegler Enters Strategic Partnership with Bicycle Therapeutics for Radioisotope Supply and Contract Development and Manufacturing of Bicycle Radio Conjugates
EQS-News: MEDICLIN presents preliminary figures for the 2024 financial year
EQS-News: MEDICLIN presents preliminary figures for the 2024 financial year
EQS-News: BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division
EQS-News: BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division
EQS-News: Eckert & Ziegler Ensures Business Continuity After Cyber-Attack
EQS-News: Eckert & Ziegler Ensures Business Continuity After Cyber-Attack
EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®